Innovation focused investing in biotechnology companies that aim to drastically improve medicine
Boxer Capital Management is a full life cycle investment firm, committed to fundamental, research-based investing in specialized and precision medicine companies across private and public markets.
Our Investment Philosophy
Through disciplined analysis, we seek to identify investment opportunities focused on transformative medical advancements in precision medicine. We invest across the drug life cycle responding to changes in the biotechnology ecosystem and investment opportunity set. Through this process, we are continuously refining and adapting our investment research and approach providing an environment for our team to compete and innovate successfully.
Our team includes scientists who have led research and discovery across multiple therapeutic indications for drugs that are treating patients today. Combining this scientific experience with nearly two decades of investment experience has allowed us to structure a repeatable process of bottom-up idea generation with top-down oversight from our founder.
Life Changing Medical Advancements
Invest to unlock better patient care and medicine for all through fundamental, scientific research
Multi-Disciplinary Analysis
Seek investments with a differentiated approach, clear rationale, and the right management team through the following lens:
- Scientific
- Clinical
- Commercial
- Regulatory
Translating Innovation Into Opportunity
Leverage the predictive value of the team’s fundamental due diligence to identify early-stage investments centered around novel, innovative drug targets
Chris’ voice on our board was pivotal as we navigated the early months of the pandemic coinciding with our intent to list on NASDAQ. Since then, I have valued Chris’ guidance as an informal advisor and friend and would pause to take any company public without his input.
Rahul Kakkar, M.D.
Former CEO, Pandion Therapeutics
After more than a decade of partnering with Aaron and the Boxer team to build Mirati, I reflect on our journey with immense pride and gratitude… Boxer was instrumental in fueling Mirati’s vision and enabling our relentless pursuit of revolutionizing precision oncology. Boxer not only provided the necessary financial support, but also served as a trusted partner to the Mirati team as we dedicated ourselves to unraveling the mysteries of KRAS, a notorious oncogene long deemed ‘undruggable.’
Chuck Baum M.D., Ph.D.
Former CEO, Mirati Therapeutics
The team at Boxer Capital is exceptional…Their scientific evaluations are remarkably thorough and stand out among their peers…They recognized, far ahead of most others, the potential of our TL1A inhibitor and the dramatic benefits it could bring.
Mark McKenna
Former CEO, Prometheus Biosciences
Each endorsement relates to activities undertaken with Boxer Capital, LLC (“Predecessor Firm”). Any reference to “Boxer Capital” refers to the Predecessor Firm. Neither Boxer Capital nor BCM provided compensation to any of these individuals for the endorsement. These endorsements may create a perceived conflict of interest as these individuals could reasonably expect that their favorable statements could influence BCM’s decisions regarding investments in their respective companies. BCM makes investment decisions independently, based on rigorous research process. Specific logos are protected trademarks of their respective owners, and Boxer Capital and BCM disclaim any endorsement from any of the entities mentioned.